MARKET

AMGN

AMGN

Amgen Inc
NASDAQ
330.17
+9.45
+2.95%
After Hours: 331.61 +1.44 +0.44% 19:59 01/06 EST
OPEN
319.49
PREV CLOSE
320.72
HIGH
330.94
LOW
318.83
VOLUME
2.72M
TURNOVER
--
52 WEEK HIGH
346.38
52 WEEK LOW
248.95
MARKET CAP
177.79B
P/E (TTM)
25.52
1D
5D
1M
3M
1Y
5Y
1D
Dow up 375 points on gains for shares of Amazon.com Inc., UnitedHealth
MarketWatch · 9h ago
Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
TipRanks · 9h ago
Alumis Skin Drug Shows Clear Benefits In Late Trials, Stock Soars
Benzinga · 10h ago
M&A News: Amgen Stock (AMGN) Brightens after $840M Capture of British Cancer-Fighting Biotech Dark Blue
TipRanks · 11h ago
Amgen Buys Dark Blue Therapeutics in Deal Worth Up to $840 Million
Dow Jones · 11h ago
Press Release: Dark Blue Therapeutics acquired by Amgen for up to $840 million
Dow Jones · 12h ago
Amgen Acquires Privately-held Dark Blue Therapeutics In $840 Mln Deal
NASDAQ · 12h ago
Amgen acquires Dark Blue Therapeutics for up to $840 million
Seeking Alpha · 12h ago
More
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.

Webull offers Amgen Inc stock information, including NASDAQ: AMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AMGN stock methods without spending real money on the virtual paper trading platform.